HUP0004369A2 - Szubsztituált aminometil-kromán-származékok alkalmazása idegdegeneráció gátlására és idegregeneráció elősegítésére szolgáló gyógyszerkészítmények előállítására - Google Patents

Szubsztituált aminometil-kromán-származékok alkalmazása idegdegeneráció gátlására és idegregeneráció elősegítésére szolgáló gyógyszerkészítmények előállítására

Info

Publication number
HUP0004369A2
HUP0004369A2 HU0004369A HUP0004369A HUP0004369A2 HU P0004369 A2 HUP0004369 A2 HU P0004369A2 HU 0004369 A HU0004369 A HU 0004369A HU P0004369 A HUP0004369 A HU P0004369A HU P0004369 A2 HUP0004369 A2 HU P0004369A2
Authority
HU
Hungary
Prior art keywords
group
neural
substituted aminomethyl
chroman derivatives
promote
Prior art date
Application number
HU0004369A
Other languages
English (en)
Inventor
Thomas Fahrig
Irene Gerlach
Ervin Horváth
Reinhard Jork
Original Assignee
Bayer Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag. filed Critical Bayer Ag.
Publication of HUP0004369A2 publication Critical patent/HUP0004369A2/hu
Publication of HUP0004369A3 publication Critical patent/HUP0004369A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány szerint alkalmazható szubsztituált amino-metil-kromán-származékok az (I) általános képletnek felelnek meg, amelyben R1 jelentése hidrogénatom, hidroxilcsoport vagy -OCH3, -OCH2CH3, -OCH(CH3)2 vagy -OCH2C(CH3)2-Cl képletű csoport, vagy R1 és R2 együttesen (a) képletű csoportot alkot, R3 jelentése ciklopentil-, ciklohexil-, cikloheptil- vagyciklooktilcsoport, vagy (b) képletű o-benzoszulfimidil-csoport, és n értéke 1, 2, 3, 4 vagy 5. A vegyületek agyi sérülések és azidegrendszer krónikus betegségei esetén elősegítik az idegekregenerálódását. Ó
HU0004369A 1997-11-24 1998-11-11 The use of substituted aminomethyl chroman derivatives for prevent neural degeneration and promote neural regeneration HUP0004369A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19751949A DE19751949A1 (de) 1997-11-24 1997-11-24 Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
PCT/EP1998/007197 WO1999026621A1 (de) 1997-11-24 1998-11-11 Verwendung von substituierten aminomethyl-chromanen zur verhinderung der neuronalen degeneration und zur förderung der neuronalen regeneration

Publications (2)

Publication Number Publication Date
HUP0004369A2 true HUP0004369A2 (hu) 2001-04-28
HUP0004369A3 HUP0004369A3 (en) 2002-04-29

Family

ID=7849618

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004369A HUP0004369A3 (en) 1997-11-24 1998-11-11 The use of substituted aminomethyl chroman derivatives for prevent neural degeneration and promote neural regeneration

Country Status (30)

Country Link
US (2) US6235774B1 (hu)
EP (1) EP1051170B1 (hu)
JP (1) JP2001523716A (hu)
KR (1) KR20010032357A (hu)
CN (1) CN1134256C (hu)
AR (1) AR016973A1 (hu)
AT (1) ATE206615T1 (hu)
AU (1) AU745759B2 (hu)
BG (1) BG64167B1 (hu)
CA (1) CA2311126A1 (hu)
DE (2) DE19751949A1 (hu)
DK (1) DK1051170T3 (hu)
ES (1) ES2164465T3 (hu)
HN (1) HN1998000169A (hu)
HU (1) HUP0004369A3 (hu)
IL (1) IL135904A (hu)
IS (1) IS5496A (hu)
MY (1) MY118414A (hu)
NO (1) NO20002638D0 (hu)
NZ (1) NZ504656A (hu)
PE (1) PE134999A1 (hu)
PL (1) PL340674A1 (hu)
PT (1) PT1051170E (hu)
RU (1) RU2217140C2 (hu)
SI (1) SI1051170T1 (hu)
SV (1) SV1998000138A (hu)
TR (1) TR200001471T2 (hu)
TW (1) TW524690B (hu)
WO (1) WO1999026621A1 (hu)
ZA (1) ZA9810668B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
KR20030016239A (ko) * 2000-03-17 2003-02-26 알콘, 인코퍼레이티드 녹내장 치료용의 5-ｈｔ２ 및 5-ｈｔ１ａ 아고니스트활성을 지닌 화합물
DE10058119A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
SE0004455D0 (sv) * 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
DE10101917A1 (de) * 2001-01-16 2002-07-18 Bayer Ag Verwendung von Chromanen
JP2004538289A (ja) * 2001-07-26 2004-12-24 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ２−［５−（４−フルオロフェニル）−３−ピリジルメチルアミノメチル］−クロマンおよびその生理学的に許容し得る塩の新規な使用
CN1303996C (zh) * 2001-09-12 2007-03-14 默克专利股份有限公司 取代的氨甲基苯并二氢吡喃在制备用于治疗运动障碍的药物中的用途
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
WO2005033093A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
DE102004017627A1 (de) * 2004-04-10 2005-10-27 Bayer Healthcare Ag Verwendung von vollen 5-HT1A-Agonisten zur Hemmung der opiat/opioid-induzierten Atemdepression
SG10202100751YA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
WO2018023072A2 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
RU2651756C1 (ru) * 2017-05-10 2018-04-23 Федеральное государственное бюджетное образовательное учреждение Высшего Образования Кубанский Государственный Медицинский Университет Министерства Здравоохранения Российской Федерации, КубГМУ Препарат для предотвращения образования глиальных рубцов
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
CA3130849A1 (en) 2019-03-14 2020-09-17 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300523A (en) 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
DE19522088A1 (de) 1995-06-19 1997-01-02 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration

Also Published As

Publication number Publication date
ZA9810668B (en) 1999-05-26
KR20010032357A (ko) 2001-04-16
BG64167B1 (bg) 2004-03-31
WO1999026621A1 (de) 1999-06-03
IS5496A (is) 2000-05-15
RU2217140C2 (ru) 2003-11-27
MY118414A (en) 2004-10-30
EP1051170A1 (de) 2000-11-15
CN1279604A (zh) 2001-01-10
EP1051170B1 (de) 2001-10-10
ATE206615T1 (de) 2001-10-15
CA2311126A1 (en) 1999-06-03
NO20002638L (no) 2000-05-23
US6331561B2 (en) 2001-12-18
AR016973A1 (es) 2001-08-01
JP2001523716A (ja) 2001-11-27
SI1051170T1 (en) 2001-12-31
IL135904A0 (en) 2001-05-20
HUP0004369A3 (en) 2002-04-29
CN1134256C (zh) 2004-01-14
IL135904A (en) 2003-07-06
DE19751949A1 (de) 1999-05-27
AU1668599A (en) 1999-06-15
HN1998000169A (es) 1999-11-03
US20010018530A1 (en) 2001-08-30
TW524690B (en) 2003-03-21
DK1051170T3 (da) 2001-12-27
TR200001471T2 (tr) 2000-10-23
PT1051170E (pt) 2002-02-28
ES2164465T3 (es) 2002-02-16
BG104466A (en) 2001-02-28
AU745759B2 (en) 2002-03-28
US6235774B1 (en) 2001-05-22
NO20002638D0 (no) 2000-05-23
PE134999A1 (es) 2000-03-05
PL340674A1 (en) 2001-02-12
SV1998000138A (es) 1999-05-25
DE59801724D1 (de) 2001-11-15
NZ504656A (en) 2002-02-01

Similar Documents

Publication Publication Date Title
HUP0004369A2 (hu) Szubsztituált aminometil-kromán-származékok alkalmazása idegdegeneráció gátlására és idegregeneráció elősegítésére szolgáló gyógyszerkészítmények előállítására
NO20025517D0 (no) Triazolderivater
FI961438A0 (fi) beta-amyloidiproteiinituotannon estäjiä
TR199902291T2 (xx) �kame edilmi� 4-Arilmetilen-2-imino-2, 3-dihidrotiazoller
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
ATE374194T1 (de) Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
ATE475418T1 (de) O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen
MXPA03010843A (es) Uso de derivados con azetidinona en el tratamiento de enfermedad de alzheimer.
DE69400799T2 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE68912419T2 (de) Verwendung von Uridin zur Behandlung nervöser Störungen.
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
TR199800041T1 (xx) Heterosiklokarboksamid t�revleri ve tedavi i�in kullan�mlar�.
BG103687A (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system
ATE297396T1 (de) Neue atropisomere von 2,3-disubstituierten-(5,6)- heteroarylkondensierten-pyrimidin-4-onen
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
GR3025950T3 (en) 2-substituted morpholine and thiomorpholine derivatives as gaba- b? antagonists
Mendelsohn The manifest dream and its use in therapy.
DK0435177T3 (da) 4-Benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-oner samt deres anvendelse som antikonvulsive midler
HRP940210A2 (en) New imidazoloquinoxalinones their production and use
BR0016415A (pt) Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico
HUP0300566A2 (hu) Galantamin alkalmazása az Alzheimer-kórral összefüggő neuropszichiátriai viselkedésformák terápiájában
ATE268599T1 (de) Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn
ES2140544T3 (es) Utilizacion de efaroxan y de sus derivados para la fabricacion de medicamentos destinados al tratamiento de las enfermedades neurodegenerativas.
HUP9701606A2 (hu) Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására